Mometasone
- Generic Name
- Mometasone
- Brand Names
- Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale
- Drug Type
- Small Molecule
- Chemical Formula
- C27H30Cl2O6
- CAS Number
- 83919-23-7
- Unique Ingredient Identifier
- 04201GDN4R
- Background
Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its ...
- Indication
Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.
...
- Associated Conditions
- Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects
- Associated Therapies
- -
Phase 2 Data on ESO-101 Suggests Efficacy Among Adults with Eosinophilic Esophagitis
New phase 2 ACESO trial findings suggest ESO-101, a novel drug delivery device for mometasone furoate, is efficacious and safe for active eosinophilic esophagitis. The trial demonstrated significant reduction in eosinophil count and improvements in endoscopic outcomes, with high adherence and excellent safety profile.
EsoCap announces publication of comprehensive Phase II
ACESO Phase II study results of ESO-101, a novel drug delivery system for eosinophilic esophagitis, published in Alimentary Pharmacology & Therapeutics. ESO-101, using mometasone furoate, demonstrated safety, efficacy, and improved histologic and endoscopic outcomes. The study highlights potential for more effective disease management.
EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101's
EsoCap announces Phase II results showing ESO-101's effectiveness in treating eosinophilic esophagitis, published in Alimentary Pharmacology & Therapeutics. ESO-101, using EsoCap's drug delivery tech, demonstrated safety, tolerability, and improved histologic and endoscopic outcomes in adults with active EoE.
EsoCap announces publication of comprehensive Phase II results
EsoCap announces Phase II results showing ESO-101's effectiveness in treating eosinophilic esophagitis, published in Alimentary Pharmacology & Therapeutics. ESO-101, using a unique drug delivery tech, demonstrated safety, tolerability, and improved histologic and endoscopic outcomes in adults with active EoE.
New FDA rules for TV drug ads: Simpler language and no distractions
New FDA rules mandate clearer drug ad risk disclosures, impacting TV and radio ads. Despite industry adoption, social media influencers promote drugs with little oversight. A proposed bill aims to regulate online drug promotions, requiring risk disclosure and payment transparency.
Asthma Drug Companies | Provides Best Medicines
Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2
Lyra Therapeutics' pivotal Phase 3 ENLIGHTEN 2 trial of LYR-210, a bioresorbable nasal implant for chronic rhinosinusitis (CRS), is fully enrolled. LYR-210 delivers six months of continuous mometasone furoate therapy. Topline results expected Q2 2025.
Organon Gets More Skin in the Game by Acquiring Roivant's Dermatology Subsidiary
Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath